"10" . "6146" . . "Cabezas-Cruz, A." . "protective immunity; IgE; responses; mice"@en . "RIV/60077344:_____/14:00436590" . . "3"^^ . . . . "2"^^ . "[67D1FF348587]" . "I" . "1"^^ . "Vald\u00E9s, James J." . "Lancet Infectious Diseases" . . "de la Fuente, J." . . . "Continuous human exploitation of environmental resources and an increase in human outdoor activities have led to more contact with arthropod vectors, promoting an emergence and resurgence of tick-borne pathogens. Clinical trials of cetuximab,1 a monoclonal antibody that inhibits epidermal growth factor receptor used for treatment of metastatic colorectal cancer, have shown that the drug produces more hypersensitivity than expected, with some fatal cases.2 Patients who developed these hypersensitivity reactions were deemed to have pre-existing IgE antibodies specifi c to the alpha-gal present in the variable portion of cetuximab.3" . "Cancer research meets tick vectors for infectious diseases" . "Vald\u00E9s, James J." . "Cancer research meets tick vectors for infectious diseases" . . "RIV/60077344:_____/14:00436590!RIV15-AV0-60077344" . "Cancer research meets tick vectors for infectious diseases"@en . "Continuous human exploitation of environmental resources and an increase in human outdoor activities have led to more contact with arthropod vectors, promoting an emergence and resurgence of tick-borne pathogens. Clinical trials of cetuximab,1 a monoclonal antibody that inhibits epidermal growth factor receptor used for treatment of metastatic colorectal cancer, have shown that the drug produces more hypersensitivity than expected, with some fatal cases.2 Patients who developed these hypersensitivity reactions were deemed to have pre-existing IgE antibodies specifi c to the alpha-gal present in the variable portion of cetuximab.3"@en . "Cancer research meets tick vectors for infectious diseases"@en . . . . . . "14" . "10.1016/S1473-3099(14)70902-8" . "000342249600012" . "1473-3099" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" .